Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Rhode Island Hospital
mi
from
Providence, RI
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
University of Tennessee, Memphis Cancer Center
mi
from
Memphis, TN
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
University of Tennessee, Memphis Cancer Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Vermont Cancer Center
mi
from
Burlington, VT
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Vermont Cancer Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Richmond
mi
from
Richmond, VA
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Richmond
mi
from
Richmond, VA
Click here to add this to my saved trials
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated:  7/19/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Topotecan in Treating Patients With Myelodysplastic Syndrome
A Randomized Phase II Trial of Oral Topotecan Given Twice a Day for 5 Days or Once a Day for 10 Days to Patients With Myelodysplastic Syndromes (MDS)
Status: Enrolling
Updated: 7/19/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis
Status: Enrolling
Updated:  7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
A Phase I Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults With Myelofibrosis
Status: Enrolling
Updated: 7/25/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Tucson, AZ
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Little Rock, AR
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Ft. Myers, FL
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Tampa, FL
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Hines, IL
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Hines, IL
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Louisville, KY
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Paducah, KY
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Lafayette, LA
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Lafayette, LA
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Jackson, MS
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Jackson, MS
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Tupelo, MS
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Tupelo, MS
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Jefferson City, MO
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Kansas City, MO
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Billings, MT
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Omaha, NE
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
New Hyde Park, NY
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Rochester, NY
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Durham, NC
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Sioux Falls, SD
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
San Antonio, TX
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  7/27/2016
Clinical Research Facility
mi
from
Norfolk, VA
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemia
A Phase III Study to Evaluate the Efficacy and Safety of Front-Line Therapy With Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 7/27/2016
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Los Robles Hospital and Medical Center
mi
from
Thousand Oaks, CA
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Los Robles Hospital and Medical Center
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Florida Cancer Specialists
mi
from
Ft. Myers, FL
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Florida Cancer Specialists
mi
from
Ft. Myers, FL
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Hematology Oncology Clinic, LLP
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Center for Cancer & Blood Disorders
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
National Capital Clinical Research Consortium
mi
from
Bethesda, MD
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
National Capital Clinical Research Consortium
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Grand Rapids Clinical Oncology Program
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Oncology Hematology Care
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
South Carolina Oncology Associates, PA
mi
from
Columbia, SC
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Chattanooga Oncology Hematology Associates
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Leading Edge Research, PA
mi
from
Arlington, TX
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Leading Edge Research, PA
mi
from
Arlington, TX
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
The Center for Cancer and Blood Disorders
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated:  7/28/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
Status: Enrolling
Updated: 7/28/2016
Peninsula Cancer Institute
mi
from
Newport News, VA
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Children's Hospital Oakland
mi
from
Oakland, CA
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Children's Hospital Oakland
mi
from
Oakland, CA
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Childrens National Medical Center
mi
from
Washington,
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated:  7/28/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Cord Blood Transplantation for Sickle Cell Anemia and Thalassemia
Sibling Donor Cord Blood Banking and Transplantation
Status: Enrolling
Updated: 7/28/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials